Document Detail


Inhibition of adriamycin cardiotoxicity by 5-fluorouracil: a potential free oxygen radical scavenger.
MedLine Citation:
PMID:  9891497     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Adriamycin (ADR), a broad spectrum anticancer agent, has a limit to total dose used, due to cumulative cardiotoxicity. This side effect has been tested in the present study in combined administration with 5-fluorouracil a cytotoxic drug that often is applied together with ADR in cancer treatment. The study was performed on Wistar rats, and the experiment consisted of weekly administration for 12 weeks of adriamycin alone, of 5-fluorouracil alone, a combination of both, and a control group (normal saline) in separate groups comprising 42 animals each. The histology of the cardiac muscle, large vessels and liver, biochemistry of serum cholesterol, triglycerides and HDL-C and oxygen free radical production were examined. It was found that addition of 5-FU to the ADR administration reduced significantly the cardiac lesions, delayed and reduced the increase of serum lipids, produced by ADR alone and oxygen free radical production was also reduced, indicating that 5-fluorouracil is acting as a scavenger of free radicals.
Authors:
G P Stathopoulos; N A Malamos; I Dontas; G Deliconstantinos; D Perrea-Kotsareli; P E Karayannacos
Related Documents :
11251527 - Patterns of referral, management and survival of patients diagnosed with prostate cance...
7523737 - Artificial neural networks in the diagnosis and prognosis of prostate cancer: a pilot s...
16985647 - Laparoscopic prostatectomy: where do we stand?
10443727 - Prostate cancer sampled on sextant needle biopsy: significance of cancer on multiple co...
24759887 - A map3k1 snp predicts survival of gastric cancer in a chinese population.
12573817 - Androgen blockade in prostate cancer in 2002: major benefits on survival in localized d...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Anticancer research     Volume:  18     ISSN:  0250-7005     ISO Abbreviation:  Anticancer Res.     Publication Date:    1998 Nov-Dec
Date Detail:
Created Date:  1999-02-11     Completed Date:  1999-02-11     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  GREECE    
Other Details:
Languages:  eng     Pagination:  4387-92     Citation Subset:  IM    
Affiliation:
Hippokration-Oncology Department, School of Medicine, University of Athens, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Alanine Transaminase / blood
Alkaline Phosphatase / blood
Animals
Aspartate Aminotransferases / blood
Body Weight / drug effects
Cholesterol / blood*
Cholesterol, HDL / blood
Doxorubicin / antagonists & inhibitors,  toxicity*
Erythrocytes / drug effects,  metabolism
Female
Fluorouracil / pharmacology*
Free Radical Scavengers*
Free Radicals / metabolism
Heart / drug effects*
Liver / cytology,  drug effects,  metabolism
Male
Myocardium / cytology,  metabolism,  pathology*
Rats
Rats, Wistar
Reference Values
Time Factors
Triglycerides / blood
gamma-Glutamyltransferase / blood
Chemical
Reg. No./Substance:
0/Cholesterol, HDL; 0/Free Radical Scavengers; 0/Free Radicals; 0/Triglycerides; 23214-92-8/Doxorubicin; 51-21-8/Fluorouracil; 57-88-5/Cholesterol; EC 2.3.2.2/gamma-Glutamyltransferase; EC 2.6.1.1/Aspartate Aminotransferases; EC 2.6.1.2/Alanine Transaminase; EC 3.1.3.1/Alkaline Phosphatase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  In vitro response of human breast cancer cell lines to the growth-inhibitory effects of styrylpyrone...
Next Document:  Preclinical studies on suicide gene therapy for head/neck cancer: a novel method for evaluation of t...